INFORM2 (clinical trials)

INFORM2 (clinical trials)

INFORM2 (Individualized therapy For Relapsed Malignancies in childhood) translates the molecular findings of the INFORM Registry (the international next-generation diagnostics platform for progressive/relapsed malignancies) into biomarker driven phase I-II trials with new targeted/immune therapies and combinations. The first trial (INFORM2-NivEnt) is open since the end of July 2019 and further trials are in preparation, all based on new preclinical data and the availability of new (targeted) drugs. The INFORM2 trial includes trial sites in several European countries and Australia.

to top